The United States of America as Represented by the Department of Health

Other

Nour Heart, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Elliott Schiffmann

Lance A Liotta

Mary Stracke

Salwa A Elgebaly

Henry Krutzch

Jun Murata

Henry C Krutzsch

Tamer Elbayoumi

The present invention provides compositions and methods for identifying, monitoring, and/or treating tissue inflammation caused by diseases or injury. Inflammatory mediators from the Nourin family are provided as diagnostic markers to detect or monitor a disease or injury that results in inflammation. In addition, the Nourin family antagonist, Nourexin-4 is provided as a therapy to treat diseases or injury. Further, cyclocreatine is provided as an inhibitor of Nourin formation, which can be used as a therapy to treat injury and inflammation.

Nourexin-4 nano-lipid emulsions

Methods and compositions that can treat a variety of tissue injuries and infections are provided. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.

Methods to prevent and treat diseases

The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.

Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy

Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.

Mitochondrial markers of ischemia

Autotaxin: motility stimulating protein useful in cancer diagnosis and

A new method of detecting cancer by determining the presence of autocrine motility factor (AMF) in the body fluid is described. The method utilizes induction of motility in suitable responder cells by a sample of the body fluid. If the responder cells demonstrate motility, cancer is indicated in the person from whom the body fluid was obtained.

Method for detecting carcinoma

The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; and antibodies to autotaxin.

Growing community of inventors

Chevy Chase, MD, United States of America

Elliott Schiffmann